We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
Read MoreHide Full Article
Eli Lilly & Company (LLY - Free Report) has priced the initial public offering of its Animal Health unit – Elanco - at $24 per share. The share price was above the expected range of $20-$23 per share.
With the IPO of 62.9 million shares of Elanco’s common stock, Lilly will raise up to $1.5 billion from the divestiture of a minority stake in the company. Lilly is expected to own a stake of approximately 82.3% in the new company, Elanco Animal Health Incorporated, giving the business a market capitalization of $8.55 billion. Elanco Animal Health is expected to start trading with the ticker symbol of ELAN on the New York Stock Exchange (NYSE) from Thursday.
So far this year, Lilly’s shares have outperformed the industry, rising 25.2% compared with a 6.3% increase for the industry.
Elanco filed a registration statement with the SEC for the Elanco IPO in August. In July, Lilly announced that it will establish Elanco as an independent publicly traded company via an IPO of only a minority stake of less than 20%. Lilly’s remaining ownership in Elanco is expected to be divested through a “tax-efficient transaction” by 2019. Lilly had been exploring strategic alternatives for this business including a sale, merger or creating a separate company through an initial public offer (IPO) for quite some time.
Elanco markets products for both food animals and companion animals. In 2017, the unit generated sales of more than $3.0 billion.
We remind investors that Pfizer (PFE - Free Report) spun off its Animal Health unit in early 2013, which started trading on NYSE under the name Zoetis, Inc. (ZTS - Free Report) . Zoetis’ stock price has almost tripled since it was separated from Pfizer. It remains to be seen if Elanco follows suit.
Shares of Novartis have gained 14.7% in the past three months. Its earnings estimates for 2018 have gone up 0.4% while that for 2019 have moved up 1.5% in the past 60 days.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
Eli Lilly & Company (LLY - Free Report) has priced the initial public offering of its Animal Health unit – Elanco - at $24 per share. The share price was above the expected range of $20-$23 per share.
With the IPO of 62.9 million shares of Elanco’s common stock, Lilly will raise up to $1.5 billion from the divestiture of a minority stake in the company. Lilly is expected to own a stake of approximately 82.3% in the new company, Elanco Animal Health Incorporated, giving the business a market capitalization of $8.55 billion. Elanco Animal Health is expected to start trading with the ticker symbol of ELAN on the New York Stock Exchange (NYSE) from Thursday.
So far this year, Lilly’s shares have outperformed the industry, rising 25.2% compared with a 6.3% increase for the industry.
Elanco filed a registration statement with the SEC for the Elanco IPO in August. In July, Lilly announced that it will establish Elanco as an independent publicly traded company via an IPO of only a minority stake of less than 20%. Lilly’s remaining ownership in Elanco is expected to be divested through a “tax-efficient transaction” by 2019. Lilly had been exploring strategic alternatives for this business including a sale, merger or creating a separate company through an initial public offer (IPO) for quite some time.
Elanco markets products for both food animals and companion animals. In 2017, the unit generated sales of more than $3.0 billion.
We remind investors that Pfizer (PFE - Free Report) spun off its Animal Health unit in early 2013, which started trading on NYSE under the name Zoetis, Inc. (ZTS - Free Report) . Zoetis’ stock price has almost tripled since it was separated from Pfizer. It remains to be seen if Elanco follows suit.
Lilly currently carries a Zacks Rank #2 (Buy). Another large-cap pharma company with the same Zacks Rank is Novartis (NVS - Free Report) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of Novartis have gained 14.7% in the past three months. Its earnings estimates for 2018 have gone up 0.4% while that for 2019 have moved up 1.5% in the past 60 days.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>